Amphetamine Sulfate

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Danger

H300 (97.9%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 48 reports by companies from 5 notifications to the ECHA C&L Inventory.

Danger

H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]

SYMPTOMS: Exposure to this compound may cause vasoconstriction, inhibition of motility of the gastrointestinal tract and bladder, dilation of the pupils, increased motor activity and mental alertness, euphoria, diminished sense of fatigue, increased wakefulness, insomnia, headache, hyperexcitability, and cardiac and gastrointestinal disturbances. Large doses may be followed by fatigue and mental depression, rise in blood pressure and mental concentration effects. Excessive use may lead to tolerance and physical dependence.

AMPHETAMINE SULFATE

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

AMPHETAMINE SULFATE TABLETS

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.